1. In a real-world setting, HbA1c improved similarly in patients initiating EQW or LIRA, and minor efficacy was observed in LIXI group. 2. Weight reducction was similar in all groups of treatment.
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1. In a real-world setting, HbA1c improved similarly in patients initiating EQW or LIRA, and minor efficacy was observed in LIXI group. 2. Weight reducction was similar in all groups of treatment. 3. The biggest proportion of treatment discontinuation was observerd among members of the LIXI group  6 (4,4%) patients were lost from follow up (4 LIRA, 2 EQW) • 26 (19,3%) patients discontinued the treatment [14(16,8%) LIRA, 1(3%)EQW and 11(50%) LIXI).
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